Stock Analysis

Hyloris Pharmaceuticals Reports Full Year 2022 Earnings

Source: Shutterstock

Hyloris Pharmaceuticals (EBR:HYL) Full Year 2022 Results

Key Financial Results

  • Net loss: €10.8m (loss narrowed by 7.0% from FY 2021).
ENXTBR:HYL Earnings and Revenue Growth March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hyloris Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Belgium.

The company's shares are up 4.1% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Hyloris Pharmaceuticals that we have uncovered.

Valuation is complex, but we're helping make it simple.

Find out whether Hyloris Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis